Dana-Farber was mentioned as one of the institutions affiliated with Harvard that benefited from research dollars from the National Institute of Health.
Dr. Edward J. Benz, Jr., talked about research to develop treatments for cancer that are more efficient and less toxic, by specifically targeting tumors using genetic analysis.
Tags: BasicResearch, TargetedTherapy
Cigall Kodach, PhD, spoke about the problems in today’s biology and medicine research on a panel at the Forbes Under 30 Summit.
Dana-Farber patient Grace Silva served as a case study of an “exceptional responder” for a treatment she underwent at the recommendation of her oncologists, Dr. Jochen Lorch and Dr. Nikhil Wagle.
Dr. Toni Choueiri led a study that found patients with non–clear cell renal cell carcinoma, PD-L1 positivity is associated with worse clinical outcomes, including a shorter overall survival and time to recurrence.
Dr. William Kaelin commented on the cancer-stem-cell model, and the possibility of controlling cancer without killing it.
Rafael Irizarry, PhD, co-led a new study investigating all stages and types of cancers that appear to share a telltale signature of widespread changes to the epigenome.
Tags: BasicResearch, Genomics
John Quackenbush, PhD, commented on a study that showed understanding a tumor's genomic profile is more likely to lead to an effective treatment.
Dr. Koen M. A. Dreijerink participated in a study that suggested the MEN1 mutation is also involved in the formation of breast cancer tumors.
Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215 | Call us toll-free: